We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Locus Pharmaceuticals has announced that it has entered into a research agreement with Ono Pharmaceutical, whereby Locus will apply its proprietary computational technologies and capabilities in chemistry, biology and crystallography to design and develop preclinical drug candidates for Ono.
Germany-based Origenis GmbH has announced that it has extended the research alliance with Alcon Research to develop small molecule drugs against important ophthalmic targets for two years.
Japanese drugmaker Taiho Pharmaceutical and sanofi-aventis have signed an agreement giving sanofi-aventis the rights to develop and market the oral anticancer agent, S-l.
Galapagos NV has announced closure on the acquisition of all the drug discovery operations of Discovery Partners International (DPI) for €4.25 million in cash.
King Pharmaceuticals, Inc. and Wyeth Pharmaceuticals, a division of Wyeth, announced today that they have entered into an Amended and Restated Co-Promotion Agreement regarding King's product ALTACE (ramipril), an angiotensin converting enzyme (ACE) inhibitor.
Par Pharmaceutical announced after the close on Wednesday that it will restate financial results for fiscal years 2004 and 2005 and the first quarter of 2006.
Alltracel Pharmaceuticals PLC said its second quarter sales jumped 19 pct on a year ago, and said it expects that level of growth to continue into the second half of the year.
AXM Pharma, Inc., a manufacturer of proprietary and generic pharmaceutical and nutraceutical products for the Chinese and other Asian markets, announced today that it has completed the acquisition of a 51% interest in Liaoning Ming Cheng Medical & Pharmaceutical Co., Ltd. ("Ming Cheng") through the issuance of 3.7 million shares of AXM Pharma's common stock.